Header

UZH-Logo

Maintenance Infos

Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study


Gasslitter, Irina; Kirsten, Natalia; Augustin, Matthias; Torz, Kaspar; Mrowietz, Ulrich; Eyerich, Kilian; Puig, Lluís; Hoetzenecker, Wolfram; Schütz-Bergmayr, Martina; Weger, Wolfgang; Wolf, Peter; Reider, Norbert; Ratzinger, Gudrun; Papageorgiou, Karolina; Meier, Thomas O; Maul, Julia-Tatjana; Anzengruber, Florian; Navarini, Alexander A (2019). Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study. Archives of Dermatological Research, 311(5):421-424.

Abstract

IL-17 blockers are among the newer anti-psoriatic treatment options and little is known about the interclass switching. We have thus initiated a multi-center, multi-national, retrospective study to assess the treatment response of patients who were switched from one IL-17 blocker to another. Analysis consisted of data from patients with moderate-to-severe psoriasis who did not respond satisfactorily to one of the available IL-17 blockers (secukinumab, ixekizumab, brodalumab) and were subsequently switched to another drug of this class. After 12 weeks of treatment, patients’ PASIs were evaluated. Treatment success was defined as reaching PASI 75 after 12 weeks. Topical treatment was allowed and used in all patients. 26 patients were included (13 male, 13 female) and 29 switches were evaluated. Overall, 29 switches in 21 patients were evaluated. 18 patients changed their therapy from secukinumab to ixekizumab, or in 7 cases to brodalumab. Brodalumab was used in 3 cases after failure of treatment with ixekizumab. Only in one case, non-response of brodalumab resulted in a therapy switch to secukinumab. In 15 (52%) cases, PASI 75 was reached. In 6 (20%) patients, the switch led to a PASI 50 response. No success of treatment was seen among 8 (28%) participants. When patients fail to respond or do not tolerate an IL-17 blocker, switching to another anti-IL-17A/RA is a promising viable option. Larger studies are needed to confirm our results.

Abstract

IL-17 blockers are among the newer anti-psoriatic treatment options and little is known about the interclass switching. We have thus initiated a multi-center, multi-national, retrospective study to assess the treatment response of patients who were switched from one IL-17 blocker to another. Analysis consisted of data from patients with moderate-to-severe psoriasis who did not respond satisfactorily to one of the available IL-17 blockers (secukinumab, ixekizumab, brodalumab) and were subsequently switched to another drug of this class. After 12 weeks of treatment, patients’ PASIs were evaluated. Treatment success was defined as reaching PASI 75 after 12 weeks. Topical treatment was allowed and used in all patients. 26 patients were included (13 male, 13 female) and 29 switches were evaluated. Overall, 29 switches in 21 patients were evaluated. 18 patients changed their therapy from secukinumab to ixekizumab, or in 7 cases to brodalumab. Brodalumab was used in 3 cases after failure of treatment with ixekizumab. Only in one case, non-response of brodalumab resulted in a therapy switch to secukinumab. In 15 (52%) cases, PASI 75 was reached. In 6 (20%) patients, the switch led to a PASI 50 response. No success of treatment was seen among 8 (28%) participants. When patients fail to respond or do not tolerate an IL-17 blocker, switching to another anti-IL-17A/RA is a promising viable option. Larger studies are needed to confirm our results.

Statistics

Citations

Dimensions.ai Metrics
35 citations in Web of Science®
38 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

1 download since deposited on 21 Aug 2019
0 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Angiology
04 Faculty of Medicine > University Hospital Zurich > Dermatology Clinic
Dewey Decimal Classification:610 Medicine & health
Scopus Subject Areas:Health Sciences > Dermatology
Uncontrolled Keywords:Dermatology, General Medicine
Language:English
Date:1 July 2019
Deposited On:21 Aug 2019 11:30
Last Modified:21 Jun 2024 02:06
Publisher:Springer
ISSN:0340-3696
OA Status:Closed
Publisher DOI:https://doi.org/10.1007/s00403-019-01907-y
PubMed ID:30879102